Vischer advises Novaremed in its acquisition of Metys Pharmaceuticals
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.
The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment.
Vischer advises Novaremed with a team led by partner Matthias Staehelin (pictured) with managing associate Vincent Reardon, senior associate Luzius Zumstein, associate Cédric Saladin (all corporate) and partner Nadia Tarolli with senior associate Adrian Briner (both tax).
